Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$0.96 - $1.78 $14,876 - $27,582
-15,496 Closed
0 $0
Q3 2021

Nov 16, 2021

SELL
$2.73 - $4.13 $311,580 - $471,365
-114,132 Reduced 88.05%
15,496 $48,000
Q2 2021

Aug 16, 2021

SELL
$2.18 - $4.29 $152,706 - $300,510
-70,049 Reduced 35.08%
129,628 $506,000
Q1 2021

May 17, 2021

BUY
$2.69 - $5.12 $60,756 - $115,640
22,586 Added 12.75%
199,677 $558,000
Q4 2020

Feb 16, 2021

SELL
$2.25 - $7.12 $27,724 - $87,732
-12,322 Reduced 6.51%
177,091 $542,000
Q3 2020

Nov 13, 2020

BUY
$3.46 - $8.39 $206,382 - $500,446
59,648 Added 45.97%
189,413 $1.15 Million
Q2 2020

Aug 14, 2020

BUY
$2.37 - $7.14 $54,332 - $163,684
22,925 Added 21.46%
129,765 $767,000
Q1 2020

May 15, 2020

BUY
$2.46 - $5.84 $3,461 - $8,216
1,407 Added 1.33%
106,840 $284,000
Q4 2019

Feb 07, 2020

SELL
$1.8 - $13.43 $12,918 - $96,387
-7,177 Reduced 6.37%
105,433 $287,000
Q3 2019

Nov 08, 2019

BUY
$8.12 - $14.54 $105,332 - $188,612
12,972 Added 13.02%
112,610 $1.37 Million
Q2 2019

Aug 09, 2019

BUY
$9.6 - $22.85 $956,524 - $2.28 Million
99,638 New
99,638 $1.14 Million

Others Institutions Holding CYCN

# of Institutions
1
Shares Held
293K
Call Options Held
0
Put Options Held
0

About Cyclerion Therapeutics, Inc.


  • Ticker CYCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,479,800
  • Market Cap $153M
  • Description
  • Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...
More about CYCN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.